LSE - Delayed Quote GBp
Oxford BioDynamics Plc (OBD.L)
0.1200 +0.0200 (+20.00%)
As of 11:25:42 BST. Market open.
Chart Range Bar
Loading chart for OBD.L
- Previous close
0.1000 - Open
0.1000 - Bid 0.0900 x --
- Ask 0.1200 x --
- Day's range
0.0900 - 0.1200 - 52-week range
0.0800 - 0.7800 - Volume
3,658,483 - Avg. Volume
15,394,922 - Market cap (intra-day)
5.149M - Beta (5Y monthly) -0.17
- PE ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings date (est.) --
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
1.00
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
www.oxfordbiodynamics.com37
Full-time employees
30 September
Fiscal year ends
Healthcare
Sector
Diagnostics & Research
Industry
Recent news
View more
Performance overview
Trailing total returns as of 14/07/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD return
OBD.L
44.19%
FTSE 100 (^FTSE)
5.28%
1-year return
OBD.L
53.85%
FTSE 100 (^FTSE)
16.20%
3-year return
OBD.L
98.97%
FTSE 100 (^FTSE)
40.63%
5-year return
OBD.L
99.80%
FTSE 100 (^FTSE)
47.45%
Analyst insights
View moreStatistics
View moreValuation measures
As of 13/07/2026
Market cap
4.29M
Enterprise value
6.06M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
2.40
Price/book (mrq)
1.32
Enterprise value/revenue
5.07
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-53.32%
Return on equity (ttm)
-214.95%
Revenue (ttm)
1.2M
Net income avi to common (ttm)
-9.87M
Diluted EPS (ttm)
-0.0000
Balance sheet and cash flow
Total cash (mrq)
2.51M
Total debt/equity (mrq)
131.61%
Levered free cash flow (ttm)
-3.91M
Compare
Select to analyse similar companies using key performance metrics; select up to four stocks.
0.5200
+0.39%
Mkt cap 302.29M
Industry Diagnostics & Research
461.80
-1.03%
Mkt cap EUR 171.615B
Industry Diagnostics & Research
462.50
-0.28%
Mkt cap EUR 171.875B
Industry Diagnostics & Research